BioLineRx Ltd. announced a private placement of 6,835,206 common shares at a price of $2.136 per share for the gross proceeds of $14.6 million on August 30, 2023. The closing of transactions is contingent upon approval by Israeli innovation authority of license agreement within four months of execution, and other closing conditions.